Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002086 · ClinicalTrials.gov registry record · Phase 2
A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection
A Phase 2 study of HIV Infections, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
- 13
- Study locations
NCT00002086: Completed Phase 2 study of HIV Infections, sponsored by Glaxo Wellcome.
NCT00002086 is a Phase 2 study of HIV Infections that has completed, run by Glaxo Wellcome. The registered enrollment target is 256 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (42% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002086, a Phase 2 study of HIV Infections, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
- 13
- Study locations
Study Summary
Primary: To determine whether the combination of zidovudine/zalcitabine/interferon alfa-n1 (Retrovir/HIVID/Wellferon) can produce complete responses (i.e., CD4 counts return to \>= 800 cells/mm3 for more than 24 weeks) in patients with virus sensitive to all three agents. To determine the antiviral effect of the combination therapies as evidenced by measures of quantitative viral load performed at select study centers only. Secondary: To determine the effectiveness of Retrovir/HIVID and Retrovir/HIVID/Wellferon in maintaining or increasing CD4 counts and preventing disease progression as evidenced by the development of an AIDS-defining indicator disease. To determine the effect of these regimens on secondary measures of clinical status (e.g., performance score, weight change, and secondary infections) and on measures of virologic activity such as serum p24 antigen. To assess the safety and tolerance of these regimens.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Zalcitabine
- DRUG Interferon alfa-n1
Study Locations (13)
California
- ViRx Inc - San Francisco
- Marin County Specialty Clinic - San Rafael
Florida
- Stratogen of South Florida - Miami Beach
- Univ of South Florida - Tampa
District of Columbia
- Georgetown Univ Med Ctr - Washington D.C.
Indiana
- Infectious Diseases Research Clinic / Indiana Univ Hosp - Indianapolis
Kansas
- Univ of Kansas School of Medicine - Wichita
New York
- North Shore Univ Hosp / Div of Infectious Diseases - Manhasset
Ohio
- Univ of Cincinnati - Cincinnati
Oregon
- Portland Veterans Adm Med Ctr / Rsch & Education Grp - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Phase | Phase 2 |
What the finished NCT00002086 record still lists
NCT00002086 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (42% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002086 lists 13 locations in 11 states (California, Florida, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00002086 about?
NCT00002086 is a clinical study titled "A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection". Primary: To determine whether the combination of zidovudine/zalcitabine/interferon alfa-n1 (Retrovir/HIVID/Wellferon) can produce complete responses (i.e., CD4 counts return to \>= 800 cells/mm3 for more than 24 weeks) in patients with virus sensitive to all three agents. To determine the antiviral ...
What is the current status of trial NCT00002086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants.
What conditions does trial NCT00002086 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002086?
The interventions under investigation include: Zidovudine (DRUG), Zalcitabine (DRUG), Interferon alfa-n1 (DRUG).
Who is sponsoring clinical trial NCT00002086?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002086 being conducted?
This trial has 13 study locations across California, District of Columbia, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002086's enrollment target sits among peer trials
256 137th of 542 higher than 406 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD